Explore the words cloud of the PREDICT project. It provides you a very rough idea of what is the project "PREDICT" about.
The following table provides information about the project.
|Coordinator Country||Israel [IL]|
|Total cost||2˙798˙450 €|
|EC max contribution||1˙958˙915 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-05-01 to 2021-04-30|
Take a look of project's partnership.
Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.
Smart Nursing BraRead More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More